11 nominees · 5 ballot items.
Elect eleven directors; approve the Amended and Restated Executive Long-Term Incentive Compensation Plan; advisory 'say-on-pay' approval of named executive officer compensation; advisory vote on frequency of future 'say-on-pay' votes (board recommends one year); and ratify Ernst & Young LLP as independent auditor for 2026.
Elect eleven Directors, each for a one-year term, as nominated by the Board.
Approve the Amended and Restated Executive Long-Term Incentive Compensation Plan (Amended Long-Term Equity Plan) increasing the share pool and extending the plan term.
This proposal asks shareholders to approve an amended and restated executive long-term incentive compensation plan that (1) sets the aggregate number of Class A shares available for awards at 800,000, (2) extends the plan termination date to March 1, 2036, and (3) preserves the CHC Committee’s discretion to set performance objectives, allocate awards between cash and equity and adjust awards for corporate events. Management frames the request as necessary to retain and motivate key executives through performance-based awards denominated in a mix of cash and restricted shares, with lengthy holding periods and anti-dilution/adjustment provisions; the company highlights that equity awards better align executives with stockholder interests and may avoid materially increasing cash compensation expense. The plan caps individual annual payouts at the greater of $12 million or the fair market value of 500,000 shares and preserves pro‑rations and pro‑rata treatment for death, disability, retirement and change-in-control events. The CHC retains broad authority to certify performance outcomes and to exercise discretion to increase or decrease awards, which creates both governance flexibility and potential agency risk if discretion is exercised inconsistently with long-term stockholder value. Management discloses historical "burn rates" and that the requested share pool would, under recent usage, likely fund awards for roughly four years, and explains the formula mechanics for converting dollar-denominated awards into restricted shares using a lower-of historical or performance-period average price. Approving the plan would maintain NACCO’s capacity to use equity to recruit and retain senior talent while limiting the near-term cash burden; opposing it would force heavier reliance on cash compensation or narrower equity usage that could hinder competitiveness. Key risks for investors include potential dilution (management quantifies the simple dilution percentage), concentrated discretion over award sizing and timing, and limited specifiers around the exact performance metrics to be used in future cycles; the board’s recommendation and the plan’s transfer/holding restrictions partially mitigate typical incentive misalignment concerns.
Non-binding 'say-on-pay' advisory vote to approve the Company's named executive officer compensation as disclosed in the proxy statement.
This non‑binding advisory proposal asks shareholders to approve the company's executive pay programs as disclosed in the proxy, effectively endorsing the CHC’s compensation design and outcomes for the named executive officers. Management argues that the program is strongly aligned with long‑term stockholder interests through a mix of cash and equity, substantial performance‑based components, lengthy holding periods for equity awards, and objective metrics tied to operating profit and ROTCE; it also highlights a history of strong shareholder support (≈97% approval in 2025). A vote FOR signals continued shareholder acceptance of the board’s pay‑for‑performance philosophy and preserves the board’s current approach; a vote AGAINST would be an advisory rebuke prompting the CHC to engage with investors and potentially modify program design or disclosure. Because the vote is non‑binding, the board retains ultimate discretion, but management commits to consider stockholder feedback. For a sophisticated evaluator, key considerations include the degree to which the disclosed metrics and discretion appropriately capture sustainable value creation, the ten‑year holding periods for restricted shares that increase alignment but also concentrate insider ownership, the CHC’s discretion to adjust payouts which can create agency risk, and the historical high approval rate which suggests limited near‑term governance tension. The decision should weigh the structural alignment mechanisms and disclosure transparency against remaining areas of discretionary authority and concentration of voting power within founding-family ownership when judging whether the pay program is likely to promote durable shareholder value.
Non-binding advisory vote to choose whether future 'say-on-pay' votes should occur every one, two, or three years; the Board recommends a vote for one year.
This non‑binding proposal asks shareholders to select a preferred frequency—one, two, or three years—for future advisory 'say‑on‑pay' votes. The board recommends an annual vote, arguing that it gives shareholders more immediate and direct feedback on executive compensation and allows the CHC to respond promptly to shareholder concerns; management notes that the result will be guidance the board will consider, even though the vote is advisory. An annual schedule increases engagement costs but provides frequent signaling and pressure for alignment; a multi‑year schedule reduces administrative burden and can stabilize long‑term incentive program design. For governance analysts, the main evaluation points are trade‑offs between responsiveness versus stability in compensation oversight, the company's stated use of say‑on‑pay results in prior years, and whether the board’s preference for annual votes reflects a commitment to investor engagement or potential sensitivity to short‑term shareholder sentiment. Given NACCO's history of high advisory support for pay and the board's explicit commitment to consider outcomes, the recommendation of 'one year' is consistent with a governance posture that prioritizes ongoing investor feedback.
Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | DIMENSIONAL FUND ADVISORS LP | 5.11% | 385,616 | $20M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2.25% | 169,962 | $9M |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 2.05% | 154,518 | $8M |
| 4 | BlackRock, Inc. | 1.77% | 133,710 | $7M |
| 5 | BlackRock, Inc. | 1.71% | 128,941 | $7M |
| 6 | Mudita Advisors LLP | 1.23% | 92,520 | $5M |
| 7 | STATE STREET CORP | 1.10% | 83,263 | $4M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.10% | 82,725 | $4M |
| 9 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 1.02% | 76,959 | $4M |
| 10 | Curbstone Financial Management Corp | 0.76% | 57,542 | $3M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.